In acute ischemic stroke or large‑vessel occlusion, how should permissive hypertension be managed, including blood pressure targets and medication choices?

Permissive Hypertension in Acute Ischemic Stroke

In acute ischemic stroke, do NOT routinely treat elevated blood pressure unless it exceeds 220/120 mmHg or the patient is receiving reperfusion therapy—permissive hypertension is the standard approach to preserve cerebral perfusion and prevent worsening ischemia.

Blood Pressure Management Strategy

For Patients NOT Receiving Reperfusion Therapy

Permissive hypertension is the cornerstone of management 1. The brain's autoregulation is impaired during acute stroke, making cerebral perfusion dependent on systemic blood pressure. Aggressive lowering risks extending the infarct.

Treatment thresholds:

• Do not treat unless SBP >220 mmHg or DBP >120 mmHg 1
• If treating extreme elevations, reduce BP by approximately 15% over the first 24 hours 1
• Never reduce by more than 25% in the first 24 hours 2, 1
• Avoid precipitous drops—use titratable IV agents 3

Critical caveat: The 2026 Cochrane review and recent trials (INTERACT4, MR-ASAP, RIGHT-2) demonstrate that intensive BP lowering before reperfusion therapy is associated with increased death and disability 4. This reinforces the permissive approach.

For Patients Receiving Thrombolysis (tPA/Alteplase)

Strict BP control is mandatory to reduce hemorrhagic transformation risk 1, 5.

Pre-thrombolysis targets:

• BP must be <185/110 mmHg before administering tPA 1, 5
• If BP cannot be controlled below this threshold, do not give tPA 3

Post-thrombolysis targets:

• Maintain BP <180/105 mmHg for 24 hours after tPA 1, 5
• Monitor BP every 15 minutes for 2 hours, then every 30 minutes for 6 hours, then hourly for 16 hours 3, 5

For Patients Receiving Mechanical Thrombectomy

Pre-thrombectomy:

• Target BP <180/105 mmHg before the procedure 6
• Avoid hypotension to maintain penumbral perfusion 7

Post-thrombectomy (recanalization-dependent):

• If successful recanalization (TICI 2b-3): Target maximum SBP <160 mmHg 7
• If persistent occlusion (TICI <2b): More permissive goals up to <180/105 mmHg 7

Medication Choices

First-line IV agents for controlled BP reduction 3, 5:

Labetalol:

• 10-20 mg IV over 1-2 minutes, may repeat once
• Or continuous infusion 2-8 mg/min
• Avoid in asthma/COPD patients

Nicardipine:

• Start 5 mg/h IV
• Titrate by 2.5 mg/h every 5-15 minutes
• Maximum 15 mg/h
• Preferred for titratable control

Clevidipine:

• Start 1-2 mg/h IV
• Double dose every 2-5 minutes until target reached
• Maximum 21 mg/h 5

Avoid:

• Sublingual nifedipine—causes precipitous, unpredictable drops 3, 8
• Sodium nitroprusside (reserve for refractory cases with DBP >140 mmHg) 3

Critical Pitfalls to Avoid

1. Overtreating moderate hypertension (SBP 140-220 mmHg) in non-thrombolysis candidates—this worsens outcomes by reducing penumbral perfusion 4, 9

2. Rapid BP drops—can extend infarct territory, especially with large vessel occlusion 1

3. Continuing home antihypertensives acutely—temporarily discontinue or reduce oral agents due to impaired swallowing and unpredictable responses 3

4. Ignoring the 2026 evidence shift—recent high-quality trials show intensive BP lowering (target <140 mmHg) before or after reperfusion increases mortality 4, 9

Monitoring Requirements

• Frequent BP checks during acute phase (every 15-60 minutes depending on intervention) 3
• Identify trends and extreme fluctuations requiring intervention 3
• Watch for neurological worsening with BP changes 1

Post-Acute Phase Management

After the acute phase (>72 hours), initiate or restart antihypertensive therapy targeting <140/90 mmHg for secondary prevention 1. Preferred regimen: ACE inhibitor plus thiazide/thiazide-like diuretic 1.